Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5304938 | 0.76 | KDM4E (0.51) | KDM4EKMT2APOLBMEN1RXFP1 | |
| SCHEMBL4155315 | 0.75 | ALDH1A1 (0.50) | ERCC5FEN1KDM4EALDH1A1 | |
| SCHEMBL4154430 | 0.74 | EGLN1 (0.47) | EGLN1KDM4EKMT2AMEN1RXFP1 | |
| SCHEMBL4155293 | 0.70 | EGLN1 (0.57) | EGLN1KDM4EKMT2AMEN1RXFP1 | |
| SCHEMBL2496013 | 0.68 | EGLN1 (0.63) | EGLN1 | |
| SCHEMBL15846569 | 0.68 | EGLN1 (0.54) | EGLN1APEX1 | |
| SCHEMBL5305369 | 0.68 | KDM4E (0.54) | KDM4EKMT2ATDP1MEN1RXFP1 | |
| SCHEMBL5308306 | 0.68 | KDM4E (0.53) | EGLN1KDM4EKMT2ATDP1MEN1 | |
| SCHEMBL5308580 | 0.67 | HIF1A (0.46) | EGLN1KDM4EKMT2ATDP1MEN1 | |
| SCHEMBL821620 | 0.66 | KMT2A (0.76) | KDM4EKMT2APOLBMEN1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-09 | — | — | US | claimed |
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| WO-2007136990-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885APEX1 1427/4885ERCC5 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.